Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Unicycive Therapeutics ( (UNCY) ) has shared an announcement.
Unicycive Therapeutics, Inc. sold 3,549,846 shares of common stock at an average price of $4.56 per share, generating net proceeds of approximately $16.3 million. This transaction, completed after June 30, 2025, under a sales agreement with Guggenheim Securities, LLC dated November 13, 2024, provides significant capital that could impact the company’s financial position and strategic initiatives.
The most recent analyst rating on (UNCY) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Unicycive Therapeutics stock, see the UNCY Stock Forecast page.
Spark’s Take on UNCY Stock
According to Spark, TipRanks’ AI Analyst, UNCY is a Underperform.
Unicycive Therapeutics has significant financial challenges, including ongoing net losses and a reliance on debt for financing, which weigh heavily on its stock score. The technical analysis reveals a bearish trend, as the stock is trading below major moving averages. Valuation metrics further dampen the attractiveness of the stock due to negative profitability indicators. Without earnings call insights or recent corporate events to improve prospects, the overall score reflects these financial and technical weaknesses.
To see Spark’s full report on UNCY stock, click here.
More about Unicycive Therapeutics
Average Trading Volume: 747,130
Technical Sentiment Signal: Sell
Current Market Cap: $59.12M
See more insights into UNCY stock on TipRanks’ Stock Analysis page.